Shin Nippon Biomedical Laboratories, Ltd. (FRA:YB3)
10.00
+0.50 (5.26%)
At close: Nov 28, 2025
FRA:YB3 Revenue
Shin Nippon Biomedical Laboratories had revenue of 8.29B JPY in the quarter ending September 30, 2025, with 19.11% growth. This brings the company's revenue in the last twelve months to 34.67B, up 28.06% year-over-year. In the fiscal year ending March 31, 2025, Shin Nippon Biomedical Laboratories had annual revenue of 32.41B with 22.54% growth.
Revenue (ttm)
34.67B JPY
Revenue Growth
+28.06%
P/S Ratio
2.05
Revenue / Employee
24.14M JPY
Employees
1,436
Market Cap
409.37M EUR
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 32.41B | 5.96B | 22.54% |
| Mar 31, 2024 | 26.45B | 1.36B | 5.42% |
| Mar 31, 2023 | 25.09B | 7.34B | 41.37% |
| Mar 31, 2022 | 17.75B | 2.64B | 17.46% |
| Mar 31, 2021 | 15.11B | 549.00M | 3.77% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Mercedes-Benz Group AG | 136.97B |
| Bayerische Motoren Werke Aktiengesellschaft | 136.42B |
| Deutsche Telekom AG | 121.02B |
| Allianz SE | 105.02B |
| Siemens Aktiengesellschaft | 78.91B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.10B |
| Siemens Energy AG | 39.08B |
| SAP SE | 36.49B |